Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 250 versus BACTOCILL IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 250 versus BACTOCILL IN PLASTIC CONTAINER.
AUGMENTIN '250' vs BACTOCILL IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to beta-lactamases, preventing hydrolysis of amoxicillin.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity essential for peptidoglycan cross-linking.
One 250 mg amoxicillin/125 mg clavulanate tablet orally every 8 hours for 7-10 days.
1-2 g intravenously every 4 hours.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours; clavulanate: 1.0-1.5 hours; prolonged in renal impairment (up to 7 hours for amoxicillin in anuria).
30-60 minutes (mean 40 min) in adults with normal renal function; prolonged to 7-10 hours in anuria. Clinical context: dosing interval adjustment required in renal impairment.
Renal: ~50-70% as amoxicillin, ~25-40% as clavulanate unchanged; biliary/fecal: minor (10-15% combined).
Primarily renal (60-70% unchanged by tubular secretion and glomerular filtration); biliary/fecal excretion accounts for <30%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic